Breakthrough Technology that Reduces Reflux to Help Maintain Catheter Patency While Providing a Safe and Effective Microbial Barrier.

Needlefree Catheter Patency Device

The first and only FDA-cleared device

shown to significantly reduce all types of

reflux into a catheter and be cleared for

use on all patients, including pediatric

and immunocompromised patients.

Neutron™

25%of Central Line Catheters

Develop a Thrombotic Partial or Full Occlusion2,3

The Clinical Impact of Central Line Catheter Occlusions

Catheter Occlusions Negatively Affect Patient Care

Despite continued efforts by healthcare practitioners, occlusions in central line and peripheral catheters (CVCs and PICCs) remain a significant issue that can result in:

> Delays in critical patient care.

> Increased risk of infection.

> Increase in healthcare costs.

Blood Reflux Is a Key Cause of Catheter Occlusions

One important cause of catheter occlusion is blood reflux1, or when blood backs up into the catheter.

> Blood reflux can lead to an intraluminal thrombus, which may result in an inability to infuse IV fluids/medications.

> An occluded catheter may lead to an inability to withdraw blood.

Current Technologies Are Limited in Their Ability to Reduce Reflux

Some devices on the market, including positive pressure needlefree connectors, attempt to address the problem.

Positive pressure devices only impact blood reflux when a syringe or administration set is disconnected.

As a result, clinicians continue to see an unacceptably high rate of occlusions in their patients.

Neutron Helps You Reduce Catheter

Occlusion by

50%4

The Neutron Catheter Patency Device May Help You Significantly Reduce Patient Care Risks Associated with Catheter Occlusions

Maintaining catheter patency and minimizing occlusions can be important steps in your efforts to enhance patient safety and improve outcomes

The Neutron catheter patency device is the first and only FDA-cleared device shown to significantly reduce all types of reflux into a catheter, and reducing reflux has been clinically shown to help reduce occlusions. Since Neutron helps you enhance patient care and safety by reducing the risk of catheter occlusions, the device may also allow you to:

> Minimize delay in therapy and procedures.

> Minimize unnecessary patient discomfort.

> Reduce length of stay.

> Decrease the need for and risks of declotting agents.

> Reduce the risk of releasing a blood clot into the bloodstream.

Neutron’s saline flush option allows you to reduce risks, cost, and time associated with Heparin use.

REFLUX

Internal Causes

> Patient Vascular Pressure Changes Caused by:

> Coughing

> Sneezing

> Movement

> Crying

External Causes

> Connection and Disconnection of a Luer

> IV Bag Running Dry or an Infusion Pump Stopping

> Syringe Plunger Rebound

Prevent all types of reflux into a catheter, including during luer connection and disconnection.

Integrate the Neutron catheter patency device into your institution’s protocols to help reduce CLABSIs.

The Neutron Catheter Patency Device is Designed to Reduce All Types of Reflux into a Catheter, Regardless of the Cause

Reflux of blood into the catheter has been shown to contribute to biofilm formation and catheter occlusion.

50%Neutron Helps

You Reduce tPA Usage by

4

Avoid Delays in Critical Patient Care

Neutron may help avoid delays in therapy of critical intravenous medications (e.g., antibiotics and oncolytics), nutritional support, and blood products.

> Neutron may help avoid delays in procedures and increased length of stay by decreasing unnecessary interventions, including administration of t-PA or other corrective actions.

Avoid Patient Discomfort and Pain

Neutron may help avoid patient discomfort and pain caused by unnecessary needlesticks, catheter restarts, and manipulating the IV site.

Because Neutron reduces the risk of thrombotic occlusions, patients may be less likely to require the use of declotting agents.

Avoid Unnecessary Costs

Neutron may help minimize unnecessary costs that add up when treating an occlusion, such as:

> Cost of staff time related to clinical intervention.

> Cost of tPA or other declotting agents.

> Wasted medications such as time-sensitive oncolytics and blood products.

> Increased patient stay from interruptions in therapy and catheter restarts.

Help Reduce Risk of Infection

In addition to taking advantage of ICU Medical’s patented design features shown to provide a safe and effective microbial barrier, Neutron may help reduce the risk of infection by:

> Preventing thrombosis, which is a breeding ground for infection.

> Minimizing IV line manipulation as an entry point for bacteria.

Reducing Catheter Occlusions with the Neutron Catheter Patency Device May Provide Real-Time Clinical Benefits

The Neutron’s unique neutral

displacement design may help

you address recent concerns

raised by the FDA regarding the

safety of positive displacement

connectors.5

During Infusion

During Aspiration

No Fluid Flow

Neutron: Better by Design

Unique Design Allows Neutron to Help Prevent Occlusions by Reducing Reflux and Maintaining Catheter Patency

Neutron’s innovative bi-directional silicone valve and internal bellows-design work together to prevent blood reflux at all times. The valve remains closed unless the Neutron is being accessed for aspiration or infusion, and the bellows give the Neutron its unique ability to absorb and physically compensate for pressure variations that typically result in blood reflux into a catheter.

During Reflux Event:The bellows give the Neutron its unique ability to absorb and physically compensate for pressure variations that typically result in blood reflux into a catheter.

Other “valved” or “anti-reflux” technologies on the market are simple, two-way check valves attached to needlefree connectors or integrated into catheter hubs.

1. When Neutron is not being accessed, the silicone seal forms a safe, swabbable barrier to bacterial ingress.

2. Upon luer access, the silicone seal is depressed and the fluid path windows are exposed through the device’s split-septum.

3. Fluid is either infused or aspirated through the connector and catheter via the dedicated straight internal fluid path.

The Neutron incorporates

ICU Medical’s patented

split-septum silicone seal and

straight internal fluid path

technology, clinically shown to

provide a “significantly reduced

bacterial transfer rate.”6

Proven to Help You Reduce Infections

Our Clinically-Proven Microbial Barrier Means that Neutron Can be an Important Part of Your Efforts to Eliminate CLABSI.6,7

If after converting all your central line IV connectors to the

Neutron catheter patency device, you do not experience a

reduction in catheter occlusion rates over the first three

months of usage, ICU Medical will pay you $100,000.*

* Certain conditions and restrictions apply. See your ICU Medical representative for details or go to http://www.icumed.com/neutron-catheter-patency-device.asp/

$100,000

ICU Medical Neutron Catheter Patency Device

Performance Guarantee

NEUTRON TECHNICAL SPECIFICATIONS

Residual Volume 0.1 mL

Flow Rate at Gravity 100 mL/minute

Blood Compatibility Yes

MRI Compatibility Yes

High Pressure Compatibility 10 mL/second

DRUG COMPATIBILIT Y

Alcohol Yes

Lipids Yes

Chlorhexidine Yes

Chemotherapy Yes

800.824.7890 | www.icumed.com©2013 ICU Medical Inc. | M1-1307 Rev. 05

1. Gorski, L A MS, RN, CS, CRNI. Central Venous Access Device Occlusions: Part 1: Thrombotic Causes and Treatment. Home Healthcare Nurse. 21:2 115-121, February 2003.

2. Stephens LC, Haire WD, Kotulak GD. Are Clinical Signs Accurate Indicators of the Cause of Central Venous Catheter Occlusion? JPEN. 19:75-79, 1995.

3. Haire W, Herbst S. Use of Alteplase (t-PA) for the Management of Thrombotic Catheter Dysfunction: Guidelines from a Consensus Conference of the National Association of Vascular Access Networks (NAVAN). Nutrition in Clinical Practice. 15:265-275, December 2000.

4. ICU Medical Study Summary. Observational In-Vivo Evaluation of the Neutron™ Needlefree Catheter Patency Device and its Effects on Catheter Occlusions in a Home Care Setting, 2011.

5. FDA Medical Device Safety Alert, July 28, 2010: Letter to Infection Control Practioners Regarding Positive Displacement Needleless Connectors (http://www.fda.gov/Medical Devices/Safety/AlertsandNotices/ucm220459.htm).

6. Ryder et al. Differences in Bacterial Transfer and Fluid Path Colonization through Needlefree Connector-Catheter Systems In Vitro. Poster presented at the 2011 Infusion Nurses Society (INS) Annual Conference, Abstract 4987.

7. Moore C RN, MBA, CIC. Maintained Low Rate of Catheter-Related Bloodstream Infections (CR-BSIs) After Discontinuation of a Luer Access Device (LAD) at an Academic Medical Center. Poster presented at the annual Association for Professionals in Infection Control and Epidemiology (APIC) conference 2010, Abstract 4-028.

8. 2011 GSX market data on single-sterile sales of standalone needleless connectors. February 27, 2012.

9. 2011 GSX market data on single-sterile sales of extension sets with needleless connectors. February 27, 2012.

Clinicians Around the World Choose ICU Medical Needlefree Connectors More than Any Other

We have a long and distinguished history of developing innovative connector technologies that improve patient and caregiver safety while helping you improve outcomes. From the original Clave® connector to the revolutionary Neutron™ Catheter Patency Device, connectors incorporating the foundational split-septum and internal blunt cannula technology from ICU Medical are chosen twice as often as any other connector technology. (8,9)